{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:05:57Z","timestamp":1778785557913,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jaci.2016.11.043","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T22:45:49Z","timestamp":1487717149000},"page":"486-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Treatment with grass allergen peptides improves symptoms of grass pollen\u2013induced allergic rhinoconjunctivitis"],"prefix":"10.1016","volume":"140","author":[{"given":"Anne K.","family":"Ellis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles W.","family":"Frankish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn E.","family":"O'Hehir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Steacy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Larch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roderick P.","family":"Hafner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2016.11.043_bib1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jaci.2010.06.050","article-title":"The epidemiology of ocular and nasal allergy in the United States, 1988-1994","volume":"126","author":"Singh","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaci.2005.05.017","article-title":"Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey","volume":"116","author":"Arbes","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jaci.2013.12.1071","article-title":"Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006","volume":"134","author":"Salo","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaip.2014.09.018","article-title":"Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy","volume":"3","author":"Nelson","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"suppl\u00a086","key":"10.1016\/j.jaci.2016.11.043_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.11.043_bib6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.otc.2011.03.006","article-title":"The allergic march: can we prevent allergies and asthma?","volume":"44","author":"Gordon","year":"2011","journal-title":"Otolaryngol Clin North Am"},{"key":"10.1016\/j.jaci.2016.11.043_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1067\/mai.2002.121317","article-title":"Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study)","volume":"109","author":"Moller","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1398-9995.2006.01068.x","article-title":"Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children","volume":"61","author":"Niggemann","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.11.043_bib9","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1398-9995.2007.01451.x","article-title":"Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study","volume":"62","author":"Jacobsen","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.11.043_bib10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jaci.2015.07.038","article-title":"Allergy immunotherapy for allergic rhinitis effectively prevents asthma: results from a large retrospective cohort study","volume":"136","author":"Schmitt","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0091-6749(97)70069-1","article-title":"Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children","volume":"99","author":"Des Roches","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib12","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1046\/j.1365-2222.2001.01161.x","article-title":"Prevention of new\u00a0sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A\u00a0six-year follow-up study","volume":"31","author":"Pajno","year":"2001","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2016.11.043_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.iac.2011.03.003","article-title":"History of immunotherapy: the first 100 years","volume":"31","author":"Fitzhugh","year":"2011","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2016.11.043_bib14","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1586\/1744666X.2014.963556","article-title":"Oral\/sublingual Phleum pretense grass tablet (Grazax\/Grastek) to treat allergic rhinitis in the USA","volume":"10","author":"Nelson","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1586\/1744666X.2014.957677","article-title":"Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience","volume":"10","author":"Didier","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1939-4551-7-6","article-title":"Sublingual immunotherapy: World Allergy Organization position paper 2013 update","volume":"7","author":"Canonica","year":"2014","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2016.11.043_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2010.11.035","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults","volume":"127","author":"Nelson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaci.2010.11.034","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents","volume":"127","author":"Blaiss","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11882-010-0172-5","article-title":"How should allergists deal with local reactions to allergen immunotherapy?","volume":"11","author":"Tankersley","year":"2011","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2016.11.043_bib20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaci.2011.12.973","article-title":"SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial","volume":"129","author":"Durham","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.anai.2014.04.008","article-title":"Patient initiation and persistence with allergen immunotherapy","volume":"113","author":"Anolik","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.anai.2014.02.006","article-title":"Diagnosis and treatment of nasal and ocular allergies: the Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys","volume":"112","author":"Blaiss","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1939-4551-7-24","article-title":"Current status of sublingual immunotherapy in the United States","volume":"7","author":"Elenburg","year":"2014","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2016.11.043_bib24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.anai.2012.12.014","article-title":"Perception and\u00a0practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey","volume":"110","author":"Sikora","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/jamainternmed.2015.2840","article-title":"Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis","volume":"175","author":"Di Bona","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.jaci.2016.11.043_bib26","first-page":"CD001936","article-title":"Allergen injection immunotherapy for seasonal allergic rhinitis","author":"Calderon","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2016.11.043_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2013.03.013","article-title":"Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy","volume":"132","author":"Kiel","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pharmthera.2005.05.004","article-title":"Peptide therapy for allergic diseases: basic mechanisms and new clinical approaches","volume":"108","author":"Larch\u00e9","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaci.2016.11.043_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.pharmthera.2008.11.007","article-title":"Allergen-related approaches to immunotherapy","volume":"121","author":"Rolland","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaci.2016.11.043_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/18715230113129990011","article-title":"T cell targeted strategies for improved efficacy and safety of specific immunotherapy for allergic disease","volume":"12","author":"Rolland","year":"2013","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"10.1016\/j.jaci.2016.11.043_bib31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0091-6749(98)70084-3","article-title":"How far can we simplify in\u00a0vitro diagnostics for grass pollen allergy?: a study with 17 whole pollen extracts and purified natural and recombinant major allergens","volume":"102","author":"van Ree","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1067\/mai.2003.1683","article-title":"Patterns of pollen cross-allergenicity","volume":"112","author":"Weber","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jaci.2008.07.018","article-title":"Allergen immunotherapy: what can and cannot be mixed?","volume":"122","author":"Esch","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11882-016-0603-z","article-title":"Pollen allergens for molecular diagnosis","volume":"16","author":"Pablos","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2016.11.043_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2222.2005.00099.x","article-title":"The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper","volume":"6","author":"Day","year":"2006","journal-title":"Clin Exp Allergy Rev"},{"key":"10.1016\/j.jaci.2016.11.043_bib36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1398-9995.2011.02590.x","article-title":"How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement","volume":"66","author":"Bousquet","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.11.043_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.anai.2013.07.019","article-title":"Environmental exposure unit: a sensitive, specific, and reproducible methodology for allergen challenge","volume":"111","author":"Ellis","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib38","first-page":"91","article-title":"Environmental exposure units for specific immunotherapy trials","volume":"97","author":"Ellis","year":"2013","journal-title":"Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess"},{"key":"10.1016\/j.jaci.2016.11.043_bib39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40413-015-0078-8","article-title":"Allergen immunotherapy on the way to\u00a0product-based evaluation\u2014a WAO statement","volume":"8","author":"Bachert","year":"2015","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2016.11.043_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11882-015-0514-4","article-title":"Controlled allergen challenge facilities and their unique contributions to allergic rhinitis research","volume":"15","author":"North","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2016.11.043_bib41","doi-asserted-by":"crossref","unstructured":"Ellis AK, Frankish CW, Armstrong K, Larch\u00e9 M, Steacy LM, Hafner RP. Treatment with synthetic peptide immuno-regulatory epitopes derived from grass allergens leads to a substantial reduction in grass allergy symptoms in the Environmental Exposure Unit. Paper presented at: AAAAI Annual Meeting; March 4, 2014; San Diego, CA.","DOI":"10.1016\/j.jaci.2013.12.1024"},{"key":"10.1016\/j.jaci.2016.11.043_bib42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1081-1206(10)61509-8","article-title":"Key pollen allergens in North America","volume":"91","author":"White","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib43","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2009.10.060","article-title":"Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System","volume":"125","author":"Cox","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib44","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2222.2009.03381.x","article-title":"The minimal clinically important difference in allergic rhinitis","volume":"40","author":"Barnes","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2016.11.043_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2006.01312.x","article-title":"Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A\u00a0statement of a World Allergy Organization (WAO) taskforce","volume":"62","author":"Canonica","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.11.043_bib46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jaci.2012.07.028","article-title":"Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study","volume":"131","author":"Patel","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/10408440590917044","article-title":"Hormetic dose-response relationships in immunology: occurrence, quantitative features of the dose response, mechanistic foundations, and clinical implications","volume":"35","author":"Calabrese","year":"2005","journal-title":"Crit Rev Toxicol"},{"key":"10.1016\/j.jaci.2016.11.043_bib48","article-title":"Molecular approaches for novel AIT vaccines. Oral Abstract Sessions OAS 1","volume":"69","author":"Jutel","year":"2014","journal-title":"Eur J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib49","unstructured":"Shamji MH, Kasche EM, Zadoyan G. Hydrolyzed Lolium perenne peptide fragments administered subcutaneously to hay fever patients induce allergen-specific IgG4 and blocking antibodies after two or more weeks of treatment. Presented at: EAACI Annual Meeting; 2015; Barcelona, Spain."},{"key":"10.1016\/j.jaci.2016.11.043_bib50","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jaci.2007.02.015","article-title":"Update on the current status of peptide immunotherapy","volume":"119","author":"Larch\u00e9","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib51","unstructured":"Muma W. Ontario grasses. 2012. Available at: http:\/\/ontariograsses.com\/main\/speciestype.php?type=GR. Accessed November 23, 2015."},{"key":"10.1016\/j.jaci.2016.11.043_bib52","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jaci.2013.02.013","article-title":"Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison","volume":"131","author":"Dretzke","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib53","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.coi.2009.07.012","article-title":"Immune tolerance in allergy","volume":"21","author":"Akdis","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.0019-2805.2001.01341.x","article-title":"IgG4 breaking the rules","volume":"105","author":"Aalberse","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2016.11.043_bib55","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2222.2006.02469.x","article-title":"Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy","volume":"36","author":"Tarzi","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2016.11.043_bib56","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0091-6749(98)70402-6","article-title":"Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy\u00a0in patients allergic to bee venom","volume":"101","author":"M\u00fcller","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib57","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0091-6749(98)70294-5","article-title":"Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats","volume":"102","author":"Pene","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib58","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1398-9995.2004.00601.x","article-title":"Cat\u00a0allergen\u00a0peptide immunotherapy reduces CD4(+) T cell responses to\u00a0cat allergen but does not alter suppression by CD4(+) CD25(+) T\u00a0cells: a double-blind placebo-controlled study","volume":"59","author":"Smith","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.11.043_bib59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0140-6736(02)09332-7","article-title":"Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial","volume":"360","author":"Oldfield","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2016.11.043_bib60","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1371\/journal.pmed.0020078","article-title":"T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity","volume":"2","author":"Verhoef","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.jaci.2016.11.043_bib61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1398-9995.2011.02759.x","article-title":"Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients","volume":"67","author":"Howarth","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.11.043_bib62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaci.2010.11.029","article-title":"Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy","volume":"127","author":"Worm","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.11.043_bib63","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/cea.12488","article-title":"Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects","volume":"45","author":"Couroux","year":"2015","journal-title":"Clin Exp Allergy"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917300374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917300374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:04:54Z","timestamp":1758791094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917300374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0091674917300374"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2016.11.043","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with grass allergen peptides improves symptoms of grass pollen\u2013induced allergic rhinoconjunctivitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2016.11.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}